Vividion Therapeutics, Inc., a clinical-stage biopharmaceutical company utilizing novel discovery technologies to unlock high-value, traditionally undruggable targets and develop small molecule precision therapeutics for devastating cancers and immune disorders, announces the acquisition of Tavros Therapeutics, Inc., a precision oncology platform company. Vividion is a wholly owned and independently operating subsidiary of Bayer AG. The addition of Tavros greatly expands Vividion’s functional genomics expertise and capabilities, bringing proprietary methods for genomic screening that can identify new target opportunities, as well as support discovery and translational efforts towards known targets.
Read the full article: Vividion Therapeutics Acquires Tavros Therapeutics to Expand Functional Genomics Capabilities and Boost Drug Discovery Platform //
Source: https://www.businesswire.com/news/home/20250108967074/en/Vividion-Therapeutics-Acquires-Tavros-Therapeutics-to-Expand-Functional-Genomics-Capabilities-and-Boost-Drug-Discovery-Platform